CATALYST PHARMA PTR
CATALYST PHARMA PTR operates in Diversified Metals & Mining.
CATALYST PHARMA PTR (CN2) - Total Liabilities
Latest total liabilities as of September 2024: €111.07 Million EUR
Based on the latest financial reports, CATALYST PHARMA PTR (CN2) has total liabilities worth €111.07 Million EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CATALYST PHARMA PTR - Total Liabilities Trend (2016–2023)
This chart illustrates how CATALYST PHARMA PTR's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CATALYST PHARMA PTR Competitors by Total Liabilities
The table below lists competitors of CATALYST PHARMA PTR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SKF AB
STU:SKFA
|
Germany | €55.64 Billion |
|
GAME HOURS Inc.
TWO:6626
|
Taiwan | NT$169.12 Million |
|
TAIYO YUDEN - Dusseldorf Stock Exchang
DU:TYC1
|
Germany | €249.59 Billion |
|
NTT DATA - Dusseldorf Stock Exchang
DU:NT5
|
Germany | €4.44 Trillion |
|
TRANSCOSMOS
BE:TSQ
|
Germany | €78.92 Billion |
|
ABENGOA YIELD
MU:AY3
|
Germany | €7.04 Billion |
Liability Composition Analysis (2016–2023)
This chart breaks down CATALYST PHARMA PTR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CATALYST PHARMA PTR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CATALYST PHARMA PTR (2016–2023)
The table below shows the annual total liabilities of CATALYST PHARMA PTR from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €82.23 Million | +9.34% |
| 2022-12-31 | €75.21 Million | +142.95% |
| 2021-12-31 | €30.96 Million | +36.04% |
| 2020-12-31 | €22.76 Million | -8.04% |
| 2019-12-31 | €24.75 Million | +156.01% |
| 2018-12-31 | €9.67 Million | +118.51% |
| 2017-12-31 | €4.42 Million | +84.48% |
| 2016-12-31 | €2.40 Million | -- |